Korean J Anesthesiol.  2003 Oct;45(4):486-491. 10.4097/kjae.2003.45.4.486.

Prophylactic Antiemetic Efficacy of Ondansetron in Gynecologic Pelviscopic Patients

• Kim DH
• Jin K

• KMID: 2299033
• DOI: http://doi.org/10.4097/kjae.2003.45.4.486

Abstract

BACKGROUND: The safety and efficacy of ondansetron were evaluated for the prophylaxis of postoperative nausea and vomiting (PONV) after pelviscopic gynecologic procedure. We compared the effects of three doses of intravenous ondansetron, 1 mg, 4 mg, and 8 mg.
METHODS
Eighty women were randomly allocated to one of 4 groups receiving 1 mg (group 1, n = 20), 4 mg (group 2, n = 20), 8 mg (group 3, n = 20) or normal saline (group 4, n = 20) at the end of pelviscopic operation. PONV were measured using a 4 point scale (0: none, 1: mild, 2: moderate, 3: severe) 1 hr, 2 hr, 6 hr, 12 hr, 24 hr after the operation and other side effects were checked.
RESULTS
Over the 24 hr study period, group 2 and 3 showed a significant lower incidence of nausea (15%, 10%) and vomiting (5%, 5%) than in group 1 (nausea: 25%, vomiting: 5%) or group 4 (nausea: 40%, vomiting: 30%). Complete response rates of each group were 80%, 90%, 90% and 50% during first 2 hrs and 50%, 80%, 75% and 30% after 2 hrs after operation. Adverse events were minor, and ondansetron treated patients had profiles similar to those of the placebo.
CONCLUSIONS
We concluded that ondansetron at 4 mg or 8 mg is a safe and effective prophylactic antiemetic for women requiring gynecologic pelviscopic surgery under general anesthesia.

Keyword

antiemetics; ondansetron; pelviscopy; postoperative nausea and vomiting (PONV)

MeSH Terms

Anesthesia, General
Antiemetics
Female
Humans
Incidence
Nausea
Ondansetron*
Postoperative Nausea and Vomiting
Vomiting
Antiemetics
Ondansetron